De Novo Gain‐Of‐Function Variations in LYN Associated With an Early‐Onset Systemic Autoinflammatory Disorder

Objective To identify the molecular basis of a severe systemic autoinflammatory disorder (SAID) and define its main phenotypic features, and to functionally assess the sequence variations identified in LYN, a gene encoding a nonreceptor tyrosine kinase. Methods We used targeted next‐generation seque...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 75; no. 3; pp. 468 - 474
Main Authors Louvrier, Camille, El Khouri, Elma, Grall Lerosey, Martine, Quartier, Pierre, Guerrot, Anne‐Marie, Bader Meunier, Brigitte, Chican, Julie, Mohammad, Malaïka, Assrawi, Eman, Daskalopoulou, Aphrodite, Arenas Garcia, Angela, Copin, Bruno, Piterboth, William, Dastot Le Moal, Florence, Karabina, Sonia A., Amselem, Serge, Giurgea, Irina
Format Journal Article
LanguageEnglish
Published Boston, USA Wiley Periodicals, Inc 01.03.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective To identify the molecular basis of a severe systemic autoinflammatory disorder (SAID) and define its main phenotypic features, and to functionally assess the sequence variations identified in LYN, a gene encoding a nonreceptor tyrosine kinase. Methods We used targeted next‐generation sequencing and in vitro functional studies of Lyn phosphorylation state and Lyn‐dependent NF‐κB activity after expression of recombinant Lyn isoforms carrying different sequence variations. Results We identified a de novo LYN variation (p.Tyr508His) in a patient presenting since birth with recurrent fever, chronic urticaria, atopic dermatitis, arthralgia, increased inflammatory biomarkers, and elevated plasma cytokine levels. We studied the consequences on Lyn phosphorylation state of the p.Tyr508His variation and of the 2 LYN variations reported so far (p.Tyr508Phe and p.Tyr508*), and found that all 3 variations prevent phosphorylation of residue 508 and lead to autophosphorylation of Tyr397. Additionally, these 3 LYN variations activate the NF‐κB pathway. These results show a gain‐of‐function effect of the variations involving Tyr508 on Lyn activity. Conclusion This study demonstrates the pathogenicity of the first 3 LYN variations identified in SAID patients and delineates the phenotypic spectrum of a disease entity characterized by severe, early‐onset, systemic inflammatory disease affecting neonates with no family history of SAID. All 3 LYN variations affect the same tyrosine residue located in the C‐terminus of Lyn, thereby demonstrating the critical role of this residue in the proper regulation of Lyn activity in humans.
Bibliography:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42354&file=art42354‐sup‐0001‐Disclosureform.pdf
Dr. El Khouri's work was supported by the EMERGENCE‐PhenomAID grant from Sorbonne Université.
Funded by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Agence Nationale de la Recherche (ANR‐17‐CE17‐0021‐01), and ImmunAID, which received funding from the European Union's Horizon 2020 research and innovation programme (grant agreement 779295).
.
Author disclosures are available at
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.42354